




Expanding blood-based risk assessment offerings with LifeLabs® p-tau181



LifeLabs® blood-based Alzheimer's disease (AD) risk assessment portfolio now includes testing for phosphorylated tau181 (p-tau181) proteins

Phosphorylated tau181 (p-tau181), one of the biomarkers involved in the diagnosis and staging of AD, has been shown to be detectable via plasma assay as it increases over time along with disease progression.^{1,2}

Plasma testing offers an effective and minimally invasive tool for assessment of cognitive decline²⁻⁴



Plasma p-tau181 concentrations increase over time with AD progression.^{1,2} Routine monitoring of p-tau181 levels via plasma is **ideal to support care pathways because it is less invasive, less expensive, and more practical than other methods.**



Combining plasma p-tau181 and Aβ42/40 biomarkers can **diagnose and identify patients who may experience faster cognitive decline.**^{3,4} This combination can also aid in determining further diagnostic testing or intervention needs.

Test code (ON)	Test name	Turnaround time	Volume
5640	LifeLabs® Phosphorylated tau181(p-tau181), Plasma	10 days	1 mL (0.5 mL minimum) plasma (EDTA lavender top)



For a more robust and less invasive risk assessment, incorporate LifeLabs® p-tau181 into your clinical care

Improvement of patient outcomes and care pathways drives our continued expansion of accessible AD and dementia risk assessment offerings within the LifeLabs® blood-based portfolio.

Visit [lifelabs.com/alzheimers-disease](https://www.lifelabs.com/alzheimers-disease) to see how we are transforming cognitive health assessment and diagnostics or [click here](#) to download requisition.

To receive the latest news and updates from LifeLabs, please join our email list by clicking the 'sign up' button.

[Sign up](#)

References

1. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. *Alzheimers Dement*. 2021;17(8):1353-1364. doi:10.1002/alz.12301 2. Lantero Rodríguez J, Karikari TK, Suárez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. *Acta Neuropathol*. 2020;140(3):267-278. doi: 10.1007/s00401-020-02195-x 3. Meyer PF, Ashton NJ, Karikari TK, et al. Plasma p-tau231, p-tau181, PET biomarkers, and cognitive change in older adults. *Ann Neurol*. 2022; 91(4): 548-560. doi:10.1002/ana.26308 4. Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. *Alzheimers Dement*. 2022;18(2):283-293. doi:10.1002/alz.12395